Loading clinical trials...
Loading clinical trials...
Gaitox :Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis an Observational Study on Gait Spatiotemporal Parameters
Conditions
Interventions
Incobotulinum toxin A
Start Date
January 1, 2014
Primary Completion Date
March 1, 2014
Completion Date
January 1, 2019
Last Updated
February 11, 2020
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07376772
NCT07426991
Lead Sponsor
Pôle Saint Hélier
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions